Results 211 to 220 of about 29,210 (297)

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment. [PDF]

BMC Cancer
Herold S, Schmidt C, Visco C, Tilch MK, Ohler A, Unterhalt M, Hoster E, Hoenig E, Singer S, Tucci A, Pott C, Ladetto M, Hess G, Dreyling M.   +13 more
europepmc   +1 more source

IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY [PDF]

, 2017
Christophe Bonnet, Thierry Lamy, Christophe Fruchart, Steven Le Gouill, K. Gunzer, Thomas Gastinne, Fabrice Jardin, Lionel Karlin, Roch Houot, Jehan Dupuis, Hervé Tilly, Gilles Salles   +11 more
openalex   +1 more source

Integrative green synthesis and molecular simulation of ibrutinib cocrystals for enhanced biopharmaceutical performance and in vivo pharmacokinetics. [PDF]

Int J Pharm X
Kara DD, Bangera PD, Keerikkadu M, Rathnanand M.   +3 more
europepmc   +1 more source

Ibrutinib outperforms FCR in CLL [PDF]

Nature Reviews Clinical Oncology, 2019
openaire   +2 more sources

Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up. [PDF]

Front Oncol
Guo Y, Shan Y, Piao Y, Chang X, Zou D, Ma Q, Wei Y, Xu G, Wang Y, Wang D, Teng L, Wu C, Zhao Z, Song T, Zhao H, Hui W, Su L, Sun W.   +17 more
europepmc   +1 more source

The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani [PDF]

, 2018
Sanjay Varikuti, Greta Volpedo, Noushin Saljoughian, Omar Hamza, Gregory Halsey, Nathan Ryan, Bren E Sedmak, Gabriella R. Seidler, Tracey L. Papenfuss, Steve Oghumu, Abhay R. Satoskar   +10 more
openalex   +1 more source

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

Blood Res
Hur JY, Lee JH, Lee JH, Park HS, Park H, Choi Y, Choi JH, Won YW, Yoon SE, Kim WS, Kim SJ.   +10 more
europepmc   +1 more source

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

, 2017
Benjamin J. Arthurs, Kathy Wunderle, Maylee Hsu, Suil Kim   +3 more
openalex   +1 more source

Gastrin-Releasing Peptide Receptors Stimulate MAPK-Mediated Growth of Lung Cancer Cells by Transactivating HER4 in a Neuregulin-1, MAP Kinase-Dependent Manner Requiring Activation of the ROS-System. [PDF]

Biology (Basel)
Moody TW, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT.   +4 more
europepmc   +1 more source